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Abstract
Germline mutations in the BRCA1 and BRCA2 genes cause hereditary breast and ovarian cancer syndrome (HBOC). Muta-
tions in these genes are usually inherited, and reports of de novo BRCA1/2 mutations are rare. To date, only one patient with 
low-level BRCA1 mutation mosaicism has been published. We report on a breast cancer patient with constitutional somatic 
mosaicism of a BRCA2 mutation. BRCA2 mutation c.9294C>G, p.(Tyr3098Ter) was detected in 20% of reads in DNA 
extracted from peripheral blood using next-generation sequencing (NGS). The BRCA2 mutation was subsequently observed 
at similar levels in normal breast tissue, adipose tissue, normal right fallopian tube tissue and ovaries of the patient, suggest-
ing that this mutation occurred early in embryonic development. This is the first case to report constitutional mosaicism for 
a BRCA2 mutation and shows that BRCA2 mosaicism can underlie early-onset breast cancer. NGS for BRCA1/2 should be 
considered for patients whose tumors harbor a BRCA1/2 mutation and for individuals suggestive of genetic predisposition 
but without a family history of HBO.
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Introduction
BRCA1- and BRCA2-associated hereditary breast and 
ovarian cancer syndrome (HBOC) is characterized by an 
increased susceptibility to breast and ovarian cancer, and to 
a lesser extent certain other cancers, especially in individu-
als with a BRCA2 germline mutation. Pathogenic variants in 
these two genes are suggested to account for approximately 
25% of inheritable breast cancers [1]. BRCA1 and BRCA2 
are the most commonly tested genes in individuals present-
ing with early-onset breast cancer, triple-negative breast 
cancer, bilateral breast cancer and familial breast/ovarian 
cancer [2].
Mutations in BRCA1/2 are inherited in an autosomal 
dominant manner, and very few cases of de novo muta-
tions have been reported. The haplotypes of many recurring 
BRCA1/2 mutations have a common ancestral origin and 
some are known to be hundreds of years old. Pathogenic 
BRCA1/2 variants thus represent a mixture of rare private 
mutations, some of which may be recent, and more common 
mutations passed down through several generations [3]. To 
the best of our knowledge, no patients with BRCA2 consti-
tutional mosaicism have been described in the literature, and 
a single patient with low-level constitutional mosaicism of 
BRCA1-mutation has been published [4].
The development of next-generation sequencing (NGS) 
technologies has revealed a significant contribution of 
mosaic mutations to cancer predisposition in an increas-
ing number of patients, such as in Li-Fraumeni syndrome 
and familial adenomatous polyposis [5, 6]. In other cancer 
predisposition syndromes, including Lynch syndrome and 
HBOC, de novo mutations and mosaicism appear to be less 
frequent [7]. While this phenomenon may be rare in HBOC, 
it is important to recognize it for proper clinical management 
and genetic counselling.
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Materials and methods
A 56-year-old female who had developed ductal carcinoma 
of the left breast at the age of 36 years was referred to the 
Department of Clinical Genetics at Helsinki University 
Hospital. Her DNA extracted from peripheral blood lym-
phocytes and tissue specimens was analyzed for a BRCA1 
and BRCA2 mutations using Ion AmpliSeq BRCA1 and 
BRCA2 Panel and Ion Torrent semiconductor sequencing 
(Ion Proton system, Thermo Fisher Scientific, Carlsbad, 
CA, USA). MLPA analysis was performed in parallel to 
exclude large deletions and duplications, employing Salsa 
MLPA probe mixes according to the manufacturer’s pro-
tocols (MRC-Holland, the Netherlands). BRCA2 variant 
was validated by Sanger sequencing using the primers F: 
5′-CTC CTG TTA GCA ATG TGT GCG-3′ and R: 5′-CCA 
AAA TGT GTG GTG ATG CTG-3′. The study was per-
formed in accordance with the Declaration of Helsinki 
and approved by the Ethical Review Board of Helsinki 
University Hospital. Informed consent was obtained from 
the patient.
Results
Histological analysis of the patient’s tumor specimen had 
confirmed an invasive ductal carcinoma, G3 (papillary, 17 
mm), with no lymph nodes affected (0/16). In immuno-
histochemistry the tumor was triple-negative with absent 
staining for estrogen receptor, progesterone receptor and 
HER2. Ki-67 and p53 stainings were positive. The patient 
had undergone radical mastectomy and axillary lymphad-
enectomy, and 20 years after the initial diagnosis, there 
had been no recurrence.
NGS analysis of patient’s peripheral blood DNA 
revealed a BRCA2 (NM_000059.3) nonsense mutation 
c.9294C>G, p.(Tyr3098Ter) leading to a premature ter-
mination codon in 20% of reads. This variant is predicted 
to result in a truncated protein or mRNA subjected to non-
sense-mediated decay. It has been observed in multiple 
individuals with breast and/or ovarian cancer (also denoted 
BRCA2 9522C>G in the literature) and has been classi-
fied pathogenic by ENIGMA-consortium in the ClinVar 
and BRCA Exchange databases [8]. MLPA analysis gave 
a normal result. To exclude technical errors, the mutation 
was subsequently re-analyzed in leucocyte DNA extracted 
from a second venipuncture, confirming the mutation 
in 20% of reads. In parallel with NGS, the sample was 
tested using Sanger sequencing, which revealed very 
weak signals representing the BRCA2 c.9294C>G muta-
tion (Fig. 1). Following the identification of the BRCA2 
mutation, the patient received genetic counselling. The 
putative mosaic nature of this mutation was discussed. 
Subsequently, the patient chose to undergo prophylactic 
mastectomy and salpingo-oophorectomy. In histological 
analysis the surgically removed tissues were cancer-free. 
DNA from five additional sites was thereafter extracted 
from fresh tissue and sequenced using NGS. These analy-
ses revealed the BRCA2 mutation c.9294C>G in 36% of 
reads derived from the right mammary gland tissue and 
in 25–29% of reads derived from the right fallopian tube, 
left and right ovaries and adipose tissue (Table 1). Breast 
tumor DNA was subsequently extracted from a paraffin-
embedded tissue block, containing approximately 40% of 
tumor cells, and BRCA2 c.9294C>G was detected in 57% 
of reads (Table 1).
Patient’s maternal aunt had deceased at age 80 years and 
had been diagnosed with breast cancer. In the first or sec-
ond degree relatives, there were no additional malignancies. 
DNA extracted from peripheral blood of proband’s mother, 
aged 89 years, was tested for the BRCA2 c.9294C>G muta-
tion, with negative results. The proband’s father had died at 
Fig. 1  Sequencing analysis of the patient’s blood sample. a NGS 
reads and b Sanger sequencing confirmation of the NGS data show-
ing the BRCA2 mutation c.9294C>G in mosaic form
Table 1  Tissue distribution of BRCA2 mutation c.9294C>G
Tissue type Read depth VAF (%)
Peripheral blood (draw 1) 2566 20
Peripheral blood (draw 2) 610 20
Mammary gland (right) 4732 36
Fallopian tube (right) 6893 29
Right ovary 3332 21
Left ovary 6315 25
Adipose tissue 6783 26
Breast cancer 308 57
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age 80 of coronary heart disease. His DNA was not available 
for analysis. Examination of SNPs on the reads spanning the 
BRCA2 c.9294C>G mutation were uninformative to deter-
mine the phase of the allele. Due to young age, genetic test-
ing of patient’s two offspring was deferred.
Discussion
In this patient constitutional mosaicism for a pathogenic 
BRCA2 variant c.9294C>G was identified as a cause of 
genetic predisposition to HBOC. The mosaic nature of the 
mutation was confirmed in two independent leucocyte DNA 
samples using NGS. In parallel, the sample was analyzed 
using Sanger sequencing to exclude any technical errors 
(Fig. 1). Detection of BRCA2 c.9294C>G mutation in sev-
eral non-cancerous tissues of this individual excluded cir-
culating tumor cells and clonal hematopoiesis as an origin. 
The mutation has most likely arisen de novo as an early 
postzygotic mutational event, as tissues originating from 
at least two germ layers were similarly involved (Table 1). 
Mesodermal derivatives include blood, ovary and adipose 
tissue, whereas e.g. mammary gland is of ectodermal origin. 
The tumor tissue was investigated to look for loss of het-
erozygosity (LOH) or a second hit. NGS analysis of paraffin-
embedded tissue block, containing approximately 40% of 
malignant cells, revealed no additional BRCA2-mutations. 
The variant allele frequency of BRCA2 c.9294C>G was 57% 
in tumor tissue suggesting possible somatic copy number 
change at this locus (Table 1). Since paternal sample was 
not available for analysis, revertant mosaicism, a spontane-
ous correction of a paternally inherited pathogenic muta-
tion leading to somatic mosaicism, could not be excluded. 
Revertant mosaicism is rare overall but a well-described 
phenomenon particularly in hematological conditions and 
skin diseases [9]. It has never been observed in HBOC or in 
phenocopies of BRCA1/2 families [10].
The prevalence of de novo and mosaic mutations in 
HBOC seems to be low. However, this phenomenon may 
have been slightly underestimated, as the family history of 
the proband is typically taken into account as a selection cri-
terion for genetic testing. Furthermore, some cases may have 
been missed prior to the use of NGS due to the limitations of 
Sanger sequencing to identify low-level mosaicism. In our 
patient, the age of onset and triple negativity were highly 
suggestive of genetic predisposition. To date, only a dozen 
of patients with de novo BRCA1/2 mutations have been 
reported [4, 10]. Interestingly, the de novo BRCA1/2 muta-
tions described in the literature have typically been identified 
in patients with early-onset cancer, possibly reflecting selec-
tion bias. Detecting de novo mosaic mutations is important 
in terms of genetic counselling. While siblings and parents 
of the proband will not be affected, the risk of transmitting 
the mutation to offspring depends on the level of mosaicism 
in patient’s germ cells, and may be different from the 50% 
chance in individuals with germline mutation. Mosaicism 
can contribute to the predicted phenotype, however, cor-
relation between disease severity and mosaicism level in 
leucocytes is inconclusive.
NGS technology has enabled high-fold coverage of 
sequenced fragments and quantification of variant allele 
frequencies (VAFs). Low VAF alone, however, is not suffi-
cient to establish somatic mosaicism in a patient. Additional 
tissue material needs to be tested to distinguish between the 
different etiologies. Considering the clinical implications, 
clinical laboratories should establish protocols to ensure 
detection of mosaic mutations and policies for verification 
of the result from additional material, such as buccal swabs, 
saliva or fibroblasts.
Although mosaicism for BRCA1/2 mutations seems to 
be rare, this and previous work demonstrates that low-level 
mosaic mutations can contribute to the etiology of breast 
cancer susceptibility [4]. This notion may have important 
implications in selected patients, and calls for additional 
attention to define the extent of this phenomenon. This study 
highlights the power of deep sequencing in detecting somatic 
mosaic mutations in various tissues and demonstrates the 
need to consider NGS in genetic testing of individuals sus-
pected of carrying a germline cancer predisposition. Espe-
cially in germline testing of patients, who have a verified 
somatic pathogenic BRCA1/2 mutation in tumor tissue, or 
with no family history of HBOC but personal history sugges-
tive of genetic predisposition, methods capable of identify-
ing low-level mosaicism should be used.
Acknowledgements Open access funding provided by University of 
Helsinki including Helsinki University Central Hospital. This work was 
supported by Finnish State Research Fund.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
 1. Lalloo F, Evans DG (2012) Familial breast cancer. Clin Genet 
82:105–114. https ://doi.org/10.1111/j.1399-0004.2012.01859 .x
310 P. Alhopuro et al.
1 3
 2. Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer 
LA, Aziz H (2017) The role of genetic testing in patients with 
breast cancer: a review. JAMA Surg 152:589–594. https ://doi.
org/10.1001/jamas urg.2017.0552
 3. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, 
Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lal-
loo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, 
Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop 
T, Easton D, Benitez J, King MC, Ponder BA, Weber B, Devilee 
P, Borg A, Narod SA, Goldgar D (1998) Haplotype and pheno-
type analysis of nine recurrent BRCA2 mutations in 111 families: 
results of an international study. Am J Hum Genet 62:1381–1388. 
https ://doi.org/10.1086/30188 5
 4. Friedman E, Efrat N, Soussan-Gutman L, Dvir A, Kaplan Y, 
Ekstein T, Nykamp K, Powers M, Rabideau M, Sorenson J, Top-
per S (2015) Low-level constitutional mosaicism of a de novo-
BRCA1 gene mutation. Br J Cancer 112:765–768. https ://doi.
org/10.1038/bjc.2015.14 ([doi])
 5. Renaux-Petel M, Charbonnier F, Théry J, Fermey P, Lienard G, 
Bou J, Coutant S, Vezain M, Kasper E, Fourneaux S, Manase 
S, Blanluet M, Leheup B, Mansuy L, Champigneulle J, Chappé 
C, Longy M, Sévenet N, Paillerets BB, Guerrini-Rousseau L, 
Brugières L, Caron O, Sabourin J, Tournier I, Baert-Desurmont 
S, Frébourg T, Bougeard G (2018) Contribution of de novo and 
mosaic TP53 mutations to Li-Fraumeni syndrome. J Med Genet 
55:173–180. https ://doi.org/10.1136/jmedg enet-2017-10497 6
 6. Spier I, Drichel D, Kerick M, Kirfel J, Horpaopan S, Laner A, 
Holzapfel S, Peters S, Adam R, Zhao B, Becker T, Lifton RP, 
Perner S, Hoffmann P, Kristiansen G, Timmermann B, Nöthen 
MM, Holinski-Feder E, Schweiger MR, Aretz S (2016) Low-level 
APC mutational mosaicism is the underlying cause in a substantial 
fraction of unexplained colorectal adenomatous polyposis cases. J 
Med Genet 53:172–179. https ://doi.org/10.1136/jmedg enet-2015-
10346 8
 7. Geurts-Giele WR, Rosenberg EH, Rens AV, Leerdam MEV, 
Dinjens WN, Bleeker FE (2019) Somatic mosaicism by a de 
novo MLH1 mutation as a cause of Lynch syndrome. Mol Genet 
Genom Med 7:e00699. https ://doi.org/10.1002/mgg3.699
 8. Lubinski J, Phelan CM, Ghadirian P, Lynch HT, Garber J, Weber 
B, Tung N, Horsman D, Isaacs C, Monteiro ANA, Sun P, Narod 
SA (2004) Cancer variation associated with the position of the 
mutation in the BRCA2 gene. Fam Cancer 3:1–10. https ://doi.
org/10.1023/B:FAME.00000 26816 .32400 .45
 9. Jonkman MF (1999) Revertant mosaicism in human genetic dis-
orders. Am J Med Genet 85:361–364. https ://doi.org/10.1002/
(sici)1096-8628(19990 806)85:43.0.co;2-e
 10. Azzollini J, Pesenti C, Ferrari L, Fontana L, Calvello M, Peis-
sel B, Portera G, Tabano S, Carcangiu ML, Riva P, Miozzo M, 
Manoukian S (2017) Revertant mosaicism for family mutations is 
not observed in BRCA1/2 phenocopies. PLoS ONE 12:e0171663. 
https ://doi.org/10.1371/journ al.pone.01716 63
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
